Dr. Tripti Singh, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 243
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
WI license 63669
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Wi Hospitals & Clinics Authority Madison, WI
- Unitypoint Health - Meriter Madison, WI
Medical groups
- University of Wisconsin Medical Foundation Inc (2,553 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 243
- Services billed
- 929
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Dialysis services, 4 or more physician visits per month (20 years or older) | 182 | 28 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 157 | 78 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 141 | 46 |
| Insertion of needle into vein for collection of blood sample | 79 | 32 |
| Hemodialysis procedure with physician evaluation | 59 | 38 |
| Established patient office or other outpatient visit, 30-39 minutes | 53 | 40 |
| Manual urinalysis test with examination using microscope, automated | 41 | 25 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 37 | 22 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 33 | 32 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lisinopril Other prescribers in Fitchburg, WI | 103 |
| Losartan Potassium Other prescribers in Fitchburg, WI | 53 |
| Amlodipine Besylate Other prescribers in Fitchburg, WI | 50 |
| Furosemide Other prescribers in Fitchburg, WI | 43 |
| Nifedipine Er (nifedipine) Other prescribers in Fitchburg, WI | 43 |
| Carvedilol Other prescribers in Fitchburg, WI | 28 |
| Spironolactone Other prescribers in Fitchburg, WI | 27 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Fitchburg, WI | 27 |
| Sevelamer Carbonate Other prescribers in Fitchburg, WI | 27 |
| Hydralazine Hcl Other prescribers in Fitchburg, WI | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $6,445 in total to this clinician.
| Travere Therapeutics, Inc. | $3,586 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,718 |
| Apellis Pharmaceuticals, Inc. | $141 |
| Speaking at a medical education program | $3,500 |
|---|---|
| Consulting Fee | $2,600 |
| Food and Beverage | $345 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Sep 12, 2025 | Speaking at a medical education program | $3,000 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Consulting Fee Fabhalta; Vanrafia · Immunology | $2,600 |
| Travere Therapeutics, Inc. Aug 20, 2025 | Speaking at a medical education program | $500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $41,684 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus
Novartis Pharmaceuticals Corporation - Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.